Ningbo David Medical Device Co Ltd

Ningbo David Medical Device Co Ltd maintains a strong liquidity position, with a current ratio of 3.71, indicating the company can cover its short-term liabilities more than three times over. The company has a net cash position, as long-term debt is minimal at 6.0 million CNY, and total liabilities are only 258.8 million CNY compared to total equity of 1.23 billion CNY. Free cash flow for the period was 29.6 million CNY, while operating cash flow was 89.2 million CNY, suggesting the company generates sufficient cash from operations to support its activities.

Profitability metrics show a return on equity of 7.06% and a return on assets of 5.84%, which are below the industry median for medical equipment firms. The company's net income of 87.05 million CNY on revenue of 584.03 million CNY results in a net margin of 14.9%, which is in line with the industry average. However, the operating margin of 16.9% (98.63 million CNY on 584.03 million CNY revenue) is slightly above the median for the sector, indicating efficient cost management.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic breakdown provided. This lack of diversification may expose the company to regional economic or regulatory risks. No major geographic markets are disclosed, but the company's primary operations are in China.

Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. Capital expenditures were negative at -55.03 million CNY, suggesting asset disposals or a reduction in capital spending. This may indicate a strategic shift or a focus on liquidity preservation.

The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The risk assessment notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints if cash flow from operations declines. No significant dilution events are expected in the near term, and the number of shares outstanding has remained unchanged between basic and diluted shares.

Recent filings and transcripts do not indicate any major corporate events or strategic shifts. The company has not disclosed any material legal or regulatory issues, and its financial statements show no signs of distress. The most recent financial data is from the latest fiscal period, with no indication of material changes in the business model or operations.